IP Library Granted Patent US 11,759,620
Granted Patent B2
US 11,759,620 · App. 17/358,738 · Granted Sep 19, 2023

Use and monitoring of inhaled nitric oxide with left ventricular assist devices

Inventors: Jim Potenziano (Binghamton, NY); Douglas Alan Greene (Basking Ridge, NJ); Craig Flanagan (Belmar, NJ)
Assignee: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
A61M60/148A61B5/02007A61B5/029A61B5/0215A61B5/4842A61B5/4848A61B5/686A61B5/7275A61B8/0883A61M60/178A61M60/20A61M60/515A61M60/538A61B5/0816A61M2202/0275A61M2205/05A61M2205/3303A61M2205/3553A61M2230/04G16H20/40G16H50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,759,620
App. No.
17/358,738
Granted
Sep 19, 2023
Kind
B2
Abstract

Described are systems and methods for administration of nitric oxide (NO) with use of left ventricular assists devices (LVADs), as well as systems and methods for monitoring the NO delivery devices and/or the LVAD.

Claims (19)

1. A method of monitoring the left ventricle of a patient with a left ventricular assist device (LVAD), the method comprising:

providing, via a display on a nitric oxide (NO) delivery device, clinician entry fields comprising pump speed, dose of inhaled NO, therapy duration, and number of times per day;

receiving input for each of the clinician entry fields;

reducing the pump speed of the LVAD to the received pump speed;

measuring one or more pulmonary hemodynamic parameters of the patient to obtain a first pulmonary hemodynamic value;

preloading the left ventricle by administering, via the NO delivery device, the received NO dose for the received therapy duration, wherein the NO dose is at a concentration of 5 to 80 ppm of NO and the therapy duration is for 5 to 30 minutes;

measuring one or more pulmonary hemodynamic parameters of the patient after or during administration of the dose of inhaled NO to obtain a second pulmonary hemodynamic value;

comparing the one or more hemodynamic parameters to a predetermined range;

adjusting the dose of inhaled NO if the one or more hemodynamic parameters are outside of the predetermined range; and

displaying the pump speed and the NO dose currently being delivered;

providing an exercise initiation button and receiving input from the exercise initiation button; and

exercising the heart, the exercising comprising:

discontinuing the inhaled NO administration; and

repeating the preloading, adjusting, and discontinuation to exercise the left ventricle of the patient's heart for the received number of times per day,

wherein the exercising steps are automated by the NO delivery device.

2. The method of claim 1 , wherein the pulmonary hemodynamic parameter is selected from left atrial pressure (LAP), pulmonary capillary wedge pressure (PCWP) and cardiac output (CO).

3. The method of claim 1 , wherein an increase in LAP and/or PCWP from the first pulmonary hemodynamic value to the second pulmonary hemodynamic value of less than 5 mm Hg indicates that the left ventricle is improving.

4. The method of claim 3 , further comprising modifying treatment if the left ventricle is improving, the modifying comprising explanting the LVAD from the patient.

5. The method of claim 1 , wherein measuring one or more pulmonary hemodynamic parameters comprises monitoring one or more output parameters of the LVAD.

Assignments (8)
SECURITY INTEREST Recorded Oct 28, 2025
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: GOLDMAN SACHS BANK USA, AS ADMINISTRATIVE AGENT
Reel/Frame 073375/0395 →
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
SECURITY INTEREST Recorded Aug 1, 2025
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 072331/0001 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →